Hopefully the results puts pressure on Pfizer given their "...$1bn-a-year smoking cessation drug Chantix has been linked to at least 544 suicides" (FinReview today)
More from the "Hoping the big pharma outfits will cough up" article...
"Invion chief Greg Collier describes the $15 million market cap minnow’s innovative smoking cessation treatment as a “huge partnering opportunity’’.
In other words, Invion has nowhere near the $10m to $20m of funds required to take its reworked respiratory drug INV102 (nadolol) to the pointy end of a full phase-three trial.
But Collier hopes that at least one of the 40 big pharma outfits contacted by Invion so far will be willing to take a punt. “We have been talking to every company you could imagine involved in respiratory diseases,’’ he says.
Invion’s hand has been strengthened by the results of its phase-two program involving 155 patients with chronic bronchitis and other airway ailments. Unlike traditional nicotine-based therapies, Invion’s beta-blocker INV102 targets the overproduction of mucus in the airway of the lung...."
IVX Price at posting:
1.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)